What are the modified hyper-CVAD regimens for the treatment of acute lymphoblastic leukemia (ALL)?

Updated: Oct 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Newer modifications of the hyper-CVAD regimen include the addition of a tyrosine kinase inhibitor in patients whose leukemia is Ph+, and of rituximab in patients whose leukemia is CD20 positive (see below). Both of these approaches have resulted in improvements in disease-free survival.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!